摘要
目的评价美金刚治疗中重度阿尔茨海默病（AD）患者的安全性。方法应用＂美金刚＂＂阿尔茨海默病＂及＂临床试验＂等关键词,在Pubmed、Cochrane图书馆、Medline、CNKI、CBM-disc及万方数据库检索,对符合纳入标准的6篇文献运用Review manager4.2软件进行Meta分析。计算比值比（OR）和95%可信区间（CI）。结果美金刚常见的不良反应为意识混沌、头痛、头晕、行走不稳及激惹。共纳入6项美金刚治疗AD的随机对照试验研究。Meta分析结果显示：美金刚组与安慰药组总的不良事件发生率的差异（OR=0.94,95%CI0.78~1.14,P=0.53）,头痛发生率差异（OR=1.37,95%CI0.51~3.67,P=0.54）,头晕发生率的差异（OR=1.04,95%CI0.72~1.5,P=0.84）,行走不稳发生率的差异（OR=1.01,95%CI0.7~1.46,P=0.97）均差异无显著性;意识混沌发生率均较高,差异有显著性（OR=1.70,95%CI0.54~0.96,P=0.03）;美金刚组激惹发生率较低,差异有极显著性（OR=0.70,95%CI0.52~0.93,P=0.01）。结论美金刚是治疗AD较为安全的的药物。
Objective To evaluate the safety of memantine in treating patients with Alzheiemr＇s disease.Methods Databases（Pubmed,Medline,Cochrane Library,CNNI,CBM-disc and Wanfang）were retrieved using
出处
《医药导报》
CAS
2010年第12期1648-1651,共4页
Herald of Medicine
关键词
美金刚
痴呆
阿尔茨海默病
不良反应
META分析
like Alzheimer
Meta-analysis
clinical trials and so on.The 6 references consistent with inclusion criteria were analyzed by reviewing manager 4.2.The odds ratio and 95%confidence interval were calculated. Results Confusion
headache
dizziness
fall and agitation were the most common adverse reactions（ADRs）.The Meta-analysis in RCTs showed that between t groups treated with memantine or placebo
no significant difference in the rate of ADRs（OR=0.94
9 5%CI 0.78-1.14
P=0.53）
headache（OR=1.37
9 5%CI 0.51-3.67
P=0.54）
dizziness（OR=1.04
9 5%CI 0.72-1.5
P=0.84）
fall（OR=1.01
9 5%CI 0.7-1.46
P=0.97）occurred.There was significant difference in the occurrence rate of confusion（OR=1.70
9 5%CI 0.54-0.96
P=0.03）
which implied the incidence of mementine was higher than that of placebo group.The agitation was significant lower in mementine（OR=0.70
9 5%CI 0.52-0.93
P=0.01）
than that in placebo group. Conclusion Meta-analysis show that memantine is a safe agent for treating Alzheiemr＇s disease.KEY WORDS Memantine
Dementia
Alzheiemr＇s disease
Adverse drug reaction
Meta-analysis
